Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
Theodore W. Laetsch(Children's Hospital of Philadelphia), Stephan A. Grupp(Children's Hospital of Philadelphia), Kara L. Davis(Stanford Medicine), André Baruchel(Université Paris Cité), Hidefumi Hiramatsu(Kyoto University), Christina Peters(Cancer Research Institute of the Slovak Academy of Sciences), Gary Douglas Myers(Baylor College of Medicine), Seong Lin Khaw(Royal Children's Hospital), Susana Rives(Hospital Sant Joan de Déu Barcelona), Peter Bader(Goethe University Frankfurt), Eneida R. Nemecek(Oregon Health & Science University), Muna Qayed(Emory University), Jochen Buechner(Oslo University Hospital), Shannon L. Maude(Children's Hospital of Philadelphia), Heather E. Stefanski(National Marrow Donor Program), Ranjan Tiwari(Novartis (India)), Joerg Krueger(Hospital for Sick Children), Barbara De Moerloose(Ghent University Hospital), Nicolas Boissel(Inserm), Michael Boyer(Chris O’Brien Lifehouse), Adriana Balduzzi(Azienda Ospedaliera San Gerardo), Gregory A. Yanik(University of Michigan), Henrique Bittencourt(Centre Hospitalier Universitaire Sainte-Justine), Darragh O’Donovan(Novartis (Ireland)), Paul L. Martin(Duke University), Michael A. Pulsipher(Primary Children's Hospital)
Cited by 369
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k